The stock of Acasti Pharma Inc (NASDAQ:ACST) is a huge mover today! About 1.37M shares traded hands or 6305.16% up from the average. Acasti Pharma Inc (NASDAQ:ACST) has declined 1.43% since April 26, 2016 and is downtrending. It has underperformed by 6.69% the S&P500.
The move comes after 5 months positive chart setup for the $14.75 million company. It was reported on Nov, 29 by Barchart.com. We have $2.07 PT which if reached, will make NASDAQ:ACST worth $737,500 more.
Analysts await Acasti Pharma Inc (NASDAQ:ACST) to report earnings on January, 10.
According to Zacks Investment Research, “Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti’s only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti’s only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.”
More important recent Acasti Pharma Inc (NASDAQ:ACST) news were published by: Streetinsider.com which released: “Form 6-K Acasti Pharma Inc. For: Nov 28” on November 28, 2016, also Marketwatch.com published article titled: “Acasti Pharma Inc.”, Quotes.Wsj.com published: “News Acasti Pharma Inc.ACST” on January 08, 2013. More interesting news about Acasti Pharma Inc (NASDAQ:ACST) was released by: 247Wallst.com and their article: “Acasti Pharma Share Gains Massive in Percentage Terms, Tiny in Dollars” with publication date: September 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.